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Abstract
Background: The gap between the level of care recommended by evidence-based clinical practice guidelines and the 
actual care delivered to patients in practice has been well established. The Canadian Diabetes Association (CDA) 
created an implementation strategy to improve the implementation of its 2008 guidelines. This study will evaluate the 
impact of the strategy to improve cardiovascular disease (CVD) screening, prevention and treatment for people with 
diabetes.
Design: A pragmatic cluster-randomized trial will be conducted to evaluate the CDA's CVD Toolkit. All family physicians 
in Ontario, Canada were randomly allocated to receive the Toolkit, which includes several printed educational materials 
targeting CVD screening, prevention and treatment, either in spring 2009 (intervention arm) or in spring 2010 (control 
arm). Randomization occurred at the level of the practice. Forty family physicians from each arm will be recruited to 
participate, and the medical records for 20 of their diabetic patients at high risk for CVD will be retrospectively 
reviewed. Outcome measures will be assessed for each patient between July 2009 and March 2010. The primary 
outcome will be that the patient is receiving a statin. Secondary outcomes will include 1) the receipt of an angiotensin 
converting enzyme inhibitor or angiotensin receptor blocker, 2) various intermediate measures (A1c, blood pressure, 
LDL-cholesterol, total-/HDL-cholesterol ratio, body mass index and waist circumference), and 3) clinical inertia (the 
failure to change therapy in response to an abnormal A1c, blood pressure or cholesterol reading). The analysis will be 
carried out using multilevel hierarchical logistic regression models to account for the clustered nature of the data. The 
group assignment will be a physician-level variable. In addition, a process evaluation study with six focus groups of 
family physicians will assess the acceptability of the CDA's Toolkit and will explore factors contributing to any change or 
lack of change in behaviour, from the perspectives of family physicians.
Discussion: Printed educational materials for physicians have been shown to exert small-to-moderate changes in 
patient care. The CDA's CVD Toolkit is an example of a practice guideline implementation strategy that can be 
disseminated to a wide audience relatively inexpensively, and so demonstrating its effectiveness at improving diabetes 
care could have important consequences for guideline developers, policy makers and clinicians.
Trial Registration: The trial is registered with http://www.clinicaltrials.gov, ID # NCT01026688
Background
Diabetes is a common and serious chronic disease. Its
prevalence is growing extremely rapidly, [1] and it is asso-
ciated with impaired quality of life, premature mortality
and significant economic costs [2-4]. One of the most
important complications of diabetes is cardiovascular
disease, as it accounts for about half of mortality in peo-
ple with diabetes [3]. Fortunately, numerous randomized
trials have shown that pharmacological and non-pharma-
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cological approaches can reduce the risk of complications
and morbidity for people with diabetes[5-8]. In particular,
multi-faceted interventions that target behaviour modifi-
cation, glycemia and cardiovascular risk factors substan-
tially reduce cardiovascular events and mortality[9,10].
However, these approaches are complex, as they require
management of the multiple risk factors that lead to com-
plications. Clinical practice guidelines (such as those pro-
duced by the Canadian Diabetes Association [CDA]) can
help health care providers and patients by synthesizing
the enormous literature on diabetes management into
specific recommendations for care. However, many stud-
ies have previously documented a gap between these rec-
ommendations and the actual care delivered to patients
with diabetes in Canada[11-14]. The lack of impact of
practice guidelines on actual clinical practice is not
unique to diabetes -- studies in a variety of clinical areas
have demonstrated this lack of effect[15-17]. Therefore,
the implementation of evidence-based guideline recom-
mendations in actual clinical practice needs to be
improved.
For the 2008 update to the guidelines, the CDA formed
a Dissemination and Implementation Committee to cre-
ate a guideline implementation strategy[18]. The first
component of this strategy was aimed at improving
adherence with the recommendations for cardiovascular
disease screening and treatment for people with diabetes,
since this is the most important complication of the dis-
ease and since evidence-based preventive interventions
are readily available. The strategy highlighted the identifi-
cation of diabetic patients at high risk for cardiovascular
events, treatment targets and methods for vascular pro-
tection, and the selection of patients and methods for
coronary artery disease screening. The objective of this
study is to evaluate the impact of the CDA's strategy to
improve cardiovascular disease screening, prevention
and treatment for people with diabetes.
Methods and design
Research design
We will conduct a pragmatic cluster-randomized con-
trolled trial to evaluate the effectiveness of the CDA's
physician-oriented cardiovascular disease toolkit to
improve the management of cardiovascular risk factors
for patients with diabetes. A "pragmatic attitude" to trial
design leads to a different type of trial answering different
questions than a traditional "explanatory attitude" to
design[19,20]. Explanatory randomized controlled trials
(RCTs) are conducted in well-resourced, idealized clinical
settings with motivated clinicians focusing on the partic-
ular clinical problem, whereas pragmatic trials are con-
ducted in real-world clinical care in a variety of practice
settings. Patients in explanatory RCTs are very highly
selected with stringent inclusion and exclusion criteria,
whereas very little selection is done in pragmatic RCTs,
leading to study populations that more closely reflect the
range of patients seen in clinical practice. Interventions
are strictly defined and enforced with close monitoring of
adherence in explanatory RCTs, while they are applied
more flexibly in pragmatic RCTs. Finally, explanatory
RCTs usually have a single primary outcome that is the
focus of the study, whereas pragmatic RCTs often exam-
ine a broad range of endpoints that may have relevance to
patients, clinicians and decision makers. As a result of
these differences, explanatory RCTs are useful to estab-
lish efficacy of treatment, whereas pragmatic RCTs can
establish effectiveness. Pragmatic trials are thus particu-
larly useful to evaluate strategies and population-based
initiatives, such as the knowledge translation strategy
being evaluated in this study.
Intervention
The cardiovascular disease toolkit was packaged in a
brightly-coloured box with CDA branding. (See Figure 1.)
The contents included an introductory letter from the
Chair of the practice guidelines' Dissemination and
Implementation Committee; an eight page summary of
s e l e c t e d  s e c t i o n s  o f  t h e  p r a c t i c e  g u i d e l i n e s  t a r g e t e d
towards primary care physicians; a four page synopsis of
the key guideline elements pertaining to cardiovascular
disease risk; a small double-sided laminated card with a
simplified algorithm for cardiovascular risk assessment,
vascular protection strategies and screening for cardio-
vascular disease; and a pad of tear-off sheets for patients
with a cardiovascular risk self-assessment tool and a list
of recommended risk reduction strategies. (See Figure 2.)
In the intervention group, the Toolkit was mailed with
the Spring 2009 edition of Canadian Diabetes, a newslet-
ter from the CDA which provides practical information
on diagnosis and treatment issues associated with diabe-
Figure 1 Packaging for the cardiovascular toolkit intervention.Shah et al. Trials 2010, 11:44
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tes that is sent quarterly to all primary care physicians in
Canada. The content of this edition of the newsletter did
not pertain to cardiovascular risk screening or treatment.
Both the Toolkit and Canadian Diabetes were packaged
together in a large mailing envelope. The control group
received  Canadian Diabetes alone in its usual shrink-
wrap packaging, and will receive the Toolkit with the
Spring 2010 edition of the newsletter.
Allocation of participants
All family physicians in Ontario were randomized to
either the intervention or control group using computer-
generated randomization. Randomization occurred at the
level of the practice based on the physicians' primary
practice address recorded with the College of Physicians
and Surgeons of Ontario, so that all physicians practicing
at a single location were assigned to the same group. This
was done to prevent contamination between physicians
in group practices who may share information and
resources. The randomization was stratified by health
region.
In addition to the randomized distribution to family
physicians in Ontario, the Toolkit was also distributed to
all endocrinologists in Ontario, and to all family physi-
cians and endocrinologists in all other Canadian prov-
inces and territories in a non-randomized fashion.
Endocrinologists will not directly form part of the study.
Study participants
From the Toolkit's mailing lists, we will randomly select
Ontario family physicians to approach about participat-
ing in a primary data abstraction study. Physicians will be
contacted by fax with a brief synopsis of the study pur-
pose and the planned data abstraction. They will be
invited to accept or decline to participate by fax or tele-
phone. Follow-up telephone calls will be made to physi-
cians who do not respond. We will recruit 40 family
physicians from each of the intervention and control
arms. For practical reasons, the recruited physicians will
practice within 150 km of the study centre, which incor-
porates both urban and rural areas. In order to increase
the likelihood that the participating physicians are repre-
sentative of typical practitioners and are not self-selected
towards good performers with an interest in diabetes
quality of care, the letter of invitation will not describe
the study in detail or what data will be collected.
Individual patients with diabetes seeing each physician
will be identified through the physician's billing records
o r  e l e c t r o n i c  h e a l t h  r e c o r d s .  W e  w i l l  r a n d o m l y  s e l e c t
from these records 20 diabetic patients per physician
aged = 18 years who were seen in the office at least once
between July 2009 and March 2010, and who fulfill the
Clinical Practice Guidelines' definition of being at "high
risk for CV events": [18]
• Men aged ≥ 45 years, women aged ≥ 50 years; or
• Men aged < 45 years and women < 50 years with at
least one of the following:
• Macrovascular disease (silent myocardial infarc-
tion, or evidence of peripheral arterial, carotid
arterial or cerebrovascular disease)
• Microvascular disease (nephropathy or retinop-
athy)
• Family history of premature coronary or cere-
brovascular disease in a first-degree relative
• Extreme level of a single risk factor (LDL-C > 5.0
mmol/L, systolic BP > 180 mmHg)
• Duration of diabetes > 15 years with age > 30
years
Patients who were concomitantly seeing endocrinolo-
gists will not be specifically excluded from the study.
A l t h o u g h  s u c h  p a t i e n t s  m a y  b e  m o r e  l i k e l y  t o  h a v e
received benefit from the Toolkit since all endocrinolo-
gists received the Toolkit in a non-randomized fashion,
less than 18% of people with diabetes in Ontario see both
endocrinologists and family physicians[21]. Any such
patients would bias the results of the study towards the
null.
Data collection and outcomes
Starting in the spring of 2010, we will perform a retro-
spective data abstraction from the paper charts and/or
electronic health records in each physician's office. For
each patient, demographic information (including date of
birth, sex and postal code of home residence) and clinical
information (including diabetes duration, comorbidities,
family history and baseline drug utilization) will be col-
lected. Outcome measures will be assessed for each
Figure 2 Contents of the Toolkit included (left to right): a synop-
sis of the guideline elements pertaining to cardiovascular disease 
risk, a laminated card with a simplified algorithm for cardiovascu-
lar risk management, and a pad of tear-off sheets for patients 
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patient for the period between July 2009 and March 2010.
The primary outcome will be that the patient is receiving
a statin (as determined by the record of a new prescrip-
tion, the record of a prescription renewal, or a notation
that the patient is taking a statin). This outcome is
selected because as a process of care outcome, it is closely
linked to physicians' behaviour and hence is more likely
to change as a result of the intervention, and because no
more than one-third of patients currently receive statins,
[13,22,23] so there is substantial opportunity for
improvement.
The other process outcome that will be evaluated is
whether the patient is receiving a prescription for an
angiotensin-converting enzyme inhibitor or angiotensin
receptor blocker. In addition, the following intermediate
outcomes will also be collected:
• A1c
• Blood pressure
• LDL-cholesterol
• Total-/HDL-cholesterol ratio
• Body mass index
• Waist circumference
When there are multiple measurements for these inter-
mediate measures for a patient, the last one during the
observation period will be used.
We will also measure "clinical inertia"[24]. For each
A1c, blood pressure or LDL-cholesterol reading that is
above the recommended clinical practice guideline tar-
get, we will determine whether, at the next patient visit,
there is notation in the chart of a recommended change:
the addition of a new medication, a dose change for an
existing medication, a dietary or physical activity recom-
mendation, etc.
The data collection will be conducted using a laptop
computer by a trained and experienced registered nurse,
blinded to group status. To protect confidentiality of per-
sonal health information, all information collected
through the data abstraction will be protected with soft-
ware that encrypts the data as they are entered. No iden-
tifying information will be collected; instead, unique
study numbers will be used for each individual. Sepa-
rately, each study subject's unique health card number
will be collected to permit future linkage with secondary
data sources. All data will be uploaded weekly via a secure
Internet connection to the study centre.
Proposed sample size
We will power the study to be able to detect an absolute
10% difference in statin prescription rates between
groups, a threshold similar to the median effect size
found in a systematic review of printed educational mate-
rials[25]. Even this modest improvement would be an
important achievement at a population level. To have 80%
power to detect this difference with alpha-error of 0.05, a
sample size of 408 per group would be needed. However,
this sample size must be inflated by a variance inflation
factor (VIF) to ensure adequate power when taking clus-
tering into account using generalized estimating equation
models[26]. The VIF is given by VIF = 1 + (n-1) × ρ,
where n is the mean cluster size and ρ is the intraclass
correlation coefficient, a measure of the degree of corre-
lation of the outcome within clusters. Previous data have
shown that ρ for appropriate statin use by diabetic
patients clustered within primary care physicians is
0.05[27]. If we assume a cluster size of 20 eligible patients
per physician (which represents a reasonable number of
patients whose data could be abstracted in two days), the
VIF is 1 + 0.05 × (20-1) = 1.95, so the actual required sam-
ple size is 796 patients in each group, or 40 physicians per
group.
Planned analyses
We hypothesize that patients whose family physicians are
in the intervention arm will have greater use of appropri-
ate medications and better achievement of targets than
patients whose family physicians are in the control arm.
The analysis to test this hypothesis will be carried out
using multilevel hierarchical logistic regression models to
account for the clustered nature of the data, i.e., patients
clustering within physicians and the attendant reduction
in statistical independence. The group assignment will be
a physician-level variable.
Process evaluation study
To facilitate the interpretation and generalizability of the
quantitative evaluations of the Toolkit's effectiveness,
additional information will be sought about the processes
and causal mechanisms through which they led or did not
lead to physician behaviour change. In a qualitative study
to follow the randomized trial, we will first assess the
acceptability of the cardiovascular tools (i.e., the useful-
ness of the tools from physicians' perspectives). Second,
we will explore the processes underlying any change or
lack of change in behaviour from the perspectives of fam-
ily physicians. It is possible that there are multiple factors
influencing the uptake of the educational tools, physi-
cians' understanding of them, as well as their ability and
interest in changing practice. For example, characteristics
of physician-patient relationships, features of their prac-
tice environments and that of the broader health care sys-
tem, or their understanding of the clinical problem itself
could all be influencing practice behaviour and the feasi-
bility of practice change. Qualitative methods are well-
suited to understanding the lived experiences of practi-
tioners in context and will be employed in the process
evaluation study [28,29].
Six focus groups will be conducted, each consisting of 8
to 10 family physicians, to evaluate the acceptability,Shah et al. Trials 2010, 11:44
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usability, sustainability, strengths and weaknesses of the
CDA's Toolkit. Focus group participants will be selected
using purposive sampling in order to obtain the perspec-
tives of those with a range of practice experiences (princi-
ple of sample heterogeneity, in keeping with qualitative
methodology)[30,31]. Participants with varying practice
types (group versus solo), years in practice, and whether
or not the physician self-identifies as a user of the Toolkit
will be sought[32,33]. A total sample size of six focus
groups (n = 48 to 60 participants) is likely to be sufficient
to achieve theoretical saturation[34].
Focus groups will be conducted in various locales, in
order to determine the extent to which practice setting
influences the uptake of the educational tools. While the
majority of focus groups will be conducted in Toronto
and the surrounding suburban area for reasons of feasi-
bility and economy, one focus group will be conducted in
a different metropolitan area and a second will be con-
ducted in a more rural/non-urban locale. Participants
will be asked for their perspectives on cardiovascular dis-
ease risk assessment and management as currently prac-
ticed and barriers/facilitators to the uptake of the
educational tools. The Toolkit will then be presented with
a simulated case, and participants will discuss the case as
a group, working together on a task that simulates real
clinical usage. Groups will discuss the characteristics of
the Toolkit that lead to their acceptability (or lack
thereof), and will discuss what elements would be useful
in future CDA Toolkits. The influence of pharmaceutical
company sponsorship of the Toolkit will be discussed.
Using the Theory of Planned Behaviour as a basis, the
focus groups will discuss the three variables known
empirically to predict behaviour: attitude (being in favour
of or against doing something), subjective norms (per-
ceived pressure from social sources to do or not to do
something), and perceived behavioural control (percep-
tion of having or not having control over their behav-
iour)[35].
Focus groups will be based on interview guides devel-
oped by experienced qualitative researchers, using the
trial results as a basis for development. Face and content
validity of the guides will be assessed by other team mem-
bers via pilot testing. Experienced qualitative researchers
will conduct the focus groups, which is essential to man-
age group dynamics, minimize social desirability bias,
and probe emergent findings in situ. All interviews will be
audio taped and transcribed verbatim and detailed field
notes will be kept of all interviews, providing two robust
sources of data for analysis. Written transcripts will be
analyzed for emergent categories and themes using con-
stant comparison within and across interviews[36]. Data
management will be facilitated using NVivo software
(version 8).
T e c h n i q u e s  f o r  e n s u r i n g  a n a l y t i c  r i g o u r  w i l l  e n t a i l
questioning, checking and theorizing in the manner out-
lined by Kvale[36]. Multiple readings of the transcripts,
with subsets of transcripts reviewed by different mem-
bers of the qualitative research team and an independent
researcher to interrogate the developing coding scheme
and emergent analysis will be employed[37]. Alternative
explanations of the data will be explored in order to
develop the most plausible and robust interpretation of
the interview findings[37]. Finally, the qualitative data
will be compared with the quantitative datasets in an
effort to triangulate and understand these results within
the context of the study as a whole[38].
Research ethics
The study has been approved by the Research Ethics
Board of Sunnybrook Health Sciences Centre, reference
number 421-2009.
Discussion
Gaps between the level of diabetes care recommended by
evidence-based practice guidelines and the actual care
delivered in clinical settings are well known. Studies using
large American national health surveys have shown that,
at a population level, diabetic patients have poor control
of vascular risk factors[39]. Only one-third of patients
had A1c levels on target (<7.0%), while more than one in
five had poor control (>9.0%). Similarly, only about one-
third achieved target blood pressure (<130/80) while 40%
had poor control (>140/90), and half had LDL-cholesterol
levels above target. Similarly poor management of cardio-
vascular risk factors has been found in population-level
studies of diabetic patients in other countries [13,40-43].
Therefore, strategies to improve the uptake of evidence-
based clinical practice guidelines for diabetes and to
increase the number of patients meeting treatment tar-
gets are urgently needed to reduce the cardiovascular risk
for these patients.
The Toolkit to be evaluated in this study is a form of
printed educational materials. The effect of printed edu-
cational materials to improve diabetes care is uncertain.
A meta-regression analysis by Shojania et al. [44] exam-
ined several different quality improvement interventions
to determine their relative effectiveness to improve glyce-
mic control among people with type 2 diabetes. Most
types of interventions led to small-to-moderate improve-
ments in glycemic control. Clinician education interven-
tions, which included printed educational materials, led
to a reduction in A1c of between 0.4 and 0.5%. However,
once the effect of other simultaneous quality improve-
ment interventions was taken into account, the effect of
clinician education on A1c was attenuated (reduction by
0.15%), and was no longer statistically significant. In clin-
ical areas outside of diabetes, the effectiveness of printedShah et al. Trials 2010, 11:44
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educational materials for clinicians to improve evidence-
based care and guideline adherence has been reviewed.
Several recent reviews have shown that they can exert a
small to moderate influence to improve care[25,45,46]
Grimshaw et al. [25] reviewed 235 studies examining
guideline dissemination and implementation strategies
published between 1976 and 1998. They found five com-
parisons of educational materials as a single intervention
that reported dichotomous process data, and the median
effect was an 8.1% absolute improvement in performance
(range 3.6% to 17%). A more recent Cochrane review, that
included studies published until 2006, found 23 studies
that compared printed educational material as a single
intervention versus no intervention[46]. The reviewed
randomized trials led to a median absolute improvement
in performance of 4.3% for categorical process measures
and a relative improvement of 13.6% for continuous pro-
cess measures.
Thus, previous research has generally supported that
clinician education via printed educational materials may
lead to modest improvements in quality of care. However,
all reviews highlighted some fundamental problems with
the primary evidence: the likelihood of publication bias,
and the fact that the reviews' results were drawn from a
small number of studies, most of which were underpow-
ered and had important methodological weaknesses,
such as inherent flaws in the study design or unit of anal-
ysis errors. Indeed, Grimshaw commented: "We would
not conclude that printed educational materials are effec-
tive, given the methodologic weaknesses of the primary
studies." [25] Instead, they stated that educational materi-
als may be effective, and given their relatively low cost
and feasibility, they should be considered to improve care.
Therefore, rigorous studies are needed to examine the
true effectiveness of printed educational materials to
drive changes in practice. Large trials of printed educa-
tional materials in this population are ongoing, [47], but
there are several reasons why this trial may be expected
to yield different results. First, the source of the interven-
tions in our study is the CDA, an advocacy and profes-
sional organization that would be reputable for diabetes
messaging among primary care physicians. Second, edu-
cational materials accompanying the release of practice
guidelines with significant publicity might have a greater
impact than educational materials released in isolation, as
the clinical problem and the physician community's
response would be more salient now. Third, one part of
the Toolkit is a practical and directive decision-making
tool with a straightforward algorithm, which may be
more actionable for clinicians than materials simply urg-
ing behaviour change. Hence, an evaluation of the CDA's
Toolkit is an important contribution to the knowledge
translation literature, because of the source, timing and
content of the materials.
Since guidelines on their own are not beneficial, effec-
tive implementation strategies for the target audience
should accompany their development. Understanding the
effectiveness of this particular approach will be useful for
guideline developers and government organizations
when limited funds are available to reach large numbers
of people. The study will increase understanding of
whether this level of intensity of implementation strategy
and this combination of factors in an intervention can
change behaviour, which will guide future implementa-
tion research.
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